Small-vessel and medium-vessel vasculitis

Arthritis Care and Research

Volumn 57, Issue 8, 2007, Pages 1552-1559

  Seo, Philip ^a   Stone, John H ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UpToDate   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; TACROLIMUS;

ANCA ASSOCIATED VASCULITIS; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DRUG EFFICACY; DRUG WITHDRAWAL; GERMANY; HUMAN; INCIDENCE; JOINT DESTRUCTION; MEDIUM VESSEL VASCULITIS; PROGNOSIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SMALL VESSEL VASCULITIS; SOLID TUMOR; SURVIVAL RATE; SYSTEMIC VASCULITIS; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BLOOD VESSELS; CHURG-STRAUSS SYNDROME; HUMANS; PROGNOSIS; REMISSION INDUCTION; VASCULITIS;

EID: 37349053441     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23105     Document Type: Review

References (46)

1. Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum 2004;51:128-39.
2. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003;49:388-93.
3. Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000;43:2481-7.
4. Carruthers DM, Watts RA, Symmons DP, Scott DG. Wegener's granulomatosis: increased incidence or increased recognition? Br J Rheumatol 1996;35:142-5.
5. Watts RA, Lane SE, Mooney J, Scott DG. Epidemiology of primary systemic vasculitis: unchanged over 15 years [abstract]. Arthritis Rheum 2004;50 Suppl 9:S270.
6. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414-9.
7. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005;53:93-9.
8. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
9. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004;33:65-72.
10. Turesson C, McClelland RL, Christianson TJ, Matteson EL. No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study. Arthritis Rheum 2004;50:3729-31.
11. Watts RA, Lane SE, Scott DG. Decrease over time in the incidence of systemic rheumatoid vasculitis [letter]. Arthritis Rheum 2005;52:1620-1.
12. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7
13. DuMouchel W, Smith ET, Beasley R, Nelson H, Yang X, Fram D, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004;26:1092-104.
14. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003;115:284-90.
15. Katsura T, Yoshida F, Takinishi Y. The Churg-Strauss syndrome after pranlukast treatment in a patient not receiving corticosteroids. Ann Intern Med 2003;139:386-7.
16. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
17. Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosini C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926-35.
18. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005;143:632-8.
19. Nachman PH, Segelmark M, Westman K, Hogan SL, Satterly KK, Jennette JC, et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999;56:1544-50.
20. Schmitt WH, Opelz G, van der Woude FJ. Renal transplantation (RTx) is safe and successful in Wegener's granulomatosis (WG): data from the Collaborative Transplant Study [abstract]. J Am Soc Nephrol 2002;13:564A-5.
21. Schmitt WH, van der Woude FJ. Organ transplantation in the vasculitides. Curr Opin Rheumatol 2003;15:22-8.
22. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-3.
23. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004;117:39-50.
24. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
25. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
26. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002;23:450-68.
27. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, et al, for the Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006;54:1608-18.
28. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
29. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
30. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-32.
31. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-7.
32. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
33. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836-40.
34. De Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998;25:492-5.
35. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Halla-han CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
36. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
37. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
38. Slot MC, Tervaert JW. Wegener's granulomatosis. Autoimmunity 2004;37:313-5.
39. Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW, Ballman KV. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J Am Coll Cardiol 2004;44:2410-1.
40. Ames PR, Steuer A, Pap A, Denman AM. Thrombosis in Behçet's disease: a retrospective survey from a single UK centre. Rheumatology (Oxford) 2001;40:652-5.
41. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behçet's disease. Am J Gastroenterol 1997;92:858-62.
42. Fischer MD, Hopewell PC. Recurrent pulmonary emboli and Buerger's disease. West J Med 1981;135:238-41.
43. Stone JH, Calabrese LH, Hoffman GS, Pusey CD, Hunder GG, Hellmann DB. Vasculitis: a collection of pearls and myths. Rheum Dis Clin North Am 2001;27:677-728, v.
44. Aveu F, Akar E, Demirkilic U, Yilmaz E, Akar N, Yalcin A. The role of prothrombotic mutations in patients with Buerger's disease. Thromb Res 2000;100:143-7.
45. Maslowski L, McBane R, Alexewicz P, Wysokinski WE. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002;7:259-64.
46. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005;142:620-6.